Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer

Nikhil Grandhi, Bindiya Patel, Olivia Aranha

Research output: Contribution to journalReview articlepeer-review


Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and mismatch repair deficient tumors.

Original languageEnglish
Article number100972
JournalSeminars in Colon and Rectal Surgery
Issue number3
StatePublished - Sep 2023


  • Chemotherapy
  • Colorectal cancer
  • Genomic profiling
  • Immunotherapy
  • Mutant KRAS/BRAF


Dive into the research topics of 'Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this